Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is anticipated to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Keros Therapeutics to post earnings of ($1.36) per share and revenue of $37.32 million for the quarter.

Keros Therapeutics Stock Performance

Shares of KROS opened at $10.79 on Tuesday. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The firm has a 50 day moving average price of $13.02 and a 200-day moving average price of $40.44. The firm has a market cap of $437.07 million, a price-to-earnings ratio of -2.07 and a beta of 1.39.

Wall Street Analyst Weigh In

KROS has been the subject of several analyst reports. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright dropped their target price on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Piper Sandler lowered their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Finally, Wedbush cut shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $47.00 to $15.00 in a report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.